A 71-year-old man presents with progressive exertional dyspnoea and bilateral leg swelling. Echocardiogram shows LVEF 35% and dilated LV. He has chronic kidney disease stage 3 (eGFR 45 mL/min/1.73 m²). According to Hypertension Canada and CKD recommendations, what is the preferred first-line antihypertensive agent to slow kidney disease progression and improve cardiovascular outcomes?